The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis

Mafalda Dias, Jean-Pierre Pignon, Christos Karapetis, Valerie Boige, Bengt Glimelius, Dina Kweekel, Primo Lara, Pierre Laurent-Puig, Eva Martinez-Balibrea, D Páez, C. Punt, Mary Redman, Giuseppe Toffoli, Mia Wadelius, Ross McKinnon, Michael Sorich

    Research output: Contribution to journalArticlepeer-review

    29 Citations (Scopus)

    Abstract

    To date, studies of irinotecan pharmacogenetics have mostly focused on the effect of the UGT1A1∗28 allele on irinotecan-related toxicity. However, the clinical utility of routine UGT1A1∗28 genotyping to pre-emptively adjust irinotecan dosage is dependent upon whether UGT1A1∗28 also affects patient survival following irinotecan therapy. Previous observational studies evaluating the influence of UGT1A1∗28 on survival have shown contradictory results. A systematic review and meta-analysis of both published and unpublished data were performed to summarize the available evidence of the relationship between the UGT1A1∗28 allele and patient survival related to irinotecan therapy. Overall and progression-free survival meta-analysis data were available for 1524 patients and 1494 patients, respectively. The difference in the survival between patients of different UGT1A1∗28 genotypes (homozygous, heterozygous or wild-type) who had received irinotecan was not found to be statistically significant. There was also no evidence of irinotecan dose, regimen or line of therapy having an impact on this association.

    Original languageEnglish
    Pages (from-to)424-431
    Number of pages8
    JournalPHARMACOGENOMICS JOURNAL
    Volume14
    Issue number5
    DOIs
    Publication statusPublished - 11 Oct 2014

    Fingerprint Dive into the research topics of 'The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis'. Together they form a unique fingerprint.

    Cite this